GT Biopharma is trading at $7.21, up 16.10% on October 15, 2026; no new company-specific announcement explaining the gain was identified. - The earlier resale registration does not establish a cause for the move. - Biotechnology-sector strength may be contributing: the XBI is up 2.20% amid positive clinical and regulatory news across the sector, but this backdrop does not confirm the cause of GT Biopharma’s move.